The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Comparative safety of futibatinib vs pemigatinib in metastatic cholangiocarcinoma: FAERS-based analysis.
 
Ajinkya Buradkar
No Relationships to Disclose
 
Dhatri Malipeddi
No Relationships to Disclose
 
Zunairah Shah
No Relationships to Disclose
 
Ahmad Al-Alwan
No Relationships to Disclose
 
Riya Patel
No Relationships to Disclose
 
Renuka Iyer
Consulting or Advisory Role - Advanced Accelerator Applications; AstraZeneca; Bayer; Eisai; Exelixis; Genentech; Incyte; Ipsen; Lexicon; Merck; Novartis; QED therapeutics; Sandoz; Sun pharma; Tersera
Research Funding - Cleveland BioLabs (Inst); Genentech/Roche (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
Other Relationship - AstraZeneca; Genentech; Replimune
 
Kannan Thanikachalam
Stock and Other Ownership Interests - Agenus; Pfizer